sj-docx-1-aop-10.1177_10600280221146878 – Supplemental material for Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective

Supplemental material, sj-docx-1-aop-10.1177_10600280221146878 for Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective by Shiraz Halloush, Nimer S. Alkhatib, Abdulaali R. Almutairi, Mathias Calamia, Hala Halawah, Mavis Obeng-Kusi, Martin Hoyle, Omar Rashdan, Jim Koeller and Ivo Abraham in Annals of Pharmacotherapy